Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behcet's disease without formation of antidrug antibodies

DM Verboom, Tim van der Houwen, JH Kappen, Paul van Daele, Wim Dik, Marco Schreurs, P.M. van Hagen, Jan van Laar

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)43-47
Number of pages5
JournalClinical & Experimental Rheumatology
Issue number6
Publication statusPublished - 2019

Cite this